Previous close | 6.65 |
Open | 6.58 |
Bid | 6.62 x 400 |
Ask | 6.71 x 400 |
Day's range | 6.50 - 6.70 |
52-week range | 5.30 - 12.15 |
Volume | |
Avg. volume | 3,397,398 |
Market cap | 5.486B |
Beta (5Y monthly) | 0.67 |
PE ratio (TTM) | 66.80 |
EPS (TTM) | 0.10 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 03 Jun 2021 |
1y target est | 15.71 |
Beleaguered Spanish drugmaker Grifols will not be required to restate its accounts for the years 2021 and 2022, market supervisor CNMV said on Thursday, as its investigation found no significant errors in the amounts it had reported. CNMV also found "no evidence that the financial debt reported by Grifols does not correspond to reality," it said. Since early January, short-sheller Gotham City Research had released three reports repeatedly accusing Grifols of overstating earnings and understating debt in its financial accounts.
Europe's main stock indices were flat on Friday, but notched strong gains over the week that saw record highs from German and French shares, while investors also analysed a U.S. jobs report for clues on the global monetary policy outlook. Technology lost 1.6% after BE Semiconductor slumped 16.1% on a media report that Joint Electron Device Engineering Council lowered certain chip standards which might delay investments into hybrid bonding technology.
Shares of Spanish drugmaker Grifols rose more than 16% on Friday morning after it said auditor KPMG approved its 2023 results with an unqualified opinion, without modifying the profit and debt ratio previously reported. Grifols last week published its 2023 results, pending an audit, which analysts said contributed to the share price's tumbling along with doubts about its cash flow for 2024. Since early January, a report by short-seller fund Gotham City Research that questioned Grifols' accounting and debt ratio has cast doubts about the company's business and wiped off billions of euros in market value.